It provokes a strong immune response: the American vaccine from COVID-19 encouraged scientists
Moderna's stock soared after it announced that a potential vaccine to prevent COVID-19 elicited a “strong” immune response in all 45 patients in the early stages of human trials. Writes about this CNBC.
Moderna shares rose more than 16%.
All 45 patients developed neutralizing antibodies, which, according to scientists, are important for creating immunity. This gives hope that the vaccine may provide some protection against coronavirus. In the study, each participant received a dose of 25, 100 or 250 micrograms, 15 people in each group. Participants received two doses of a potential vaccine.
After two shots, the vaccine elicited a "strong" immune response in all participants, according to a company spokesman. The company said the levels of neutralizing antibodies in patients in the high-dose group were four times higher than in recovered COVID-19 patients.
“These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a sustained immune response regardless of dose. The company selected 100 mcg as the optimal dose for the Phase 3 study, said Moderna Chief Medical Officer Tal Zachs. "We look forward to starting a Phase 3 study of mRNA-1273 this month to demonstrate the ability of our vaccine to significantly reduce the risk of COVID-19."
In May, the company released preliminary information about the early stages of testing, but the data were insufficient, and therefore the study has not yet been reviewed.
The company said the vaccine was generally well tolerated, but more than half of the participants reported mild or moderate symptoms, such as fatigue, muscle pain, or pain at the injection site.
Evaluation of the resistance of the immune response continues, and participants will be monitored for one year after vaccination.
According to data compiled by Johns Hopkins University, Moderna is one of several developers of a potential vaccine against COVID-19. According to the World Health Organization (WHO), more than 100 vaccines are being developed in the world.
Moderna previously announced that it will begin testing the vaccine on July 27. The study will bring together 30 participants in 000 cities. Participants in the experimental group will receive a dose of 87 μg of the potential vaccine on the first day and after another 100 days. Some patients will also receive a placebo.
The experimental Moderna vaccine contains genetic material called messenger RNA or mRNA. mRNA is the genetic code that tells cells what they need to build - in this case, an antigen that can trigger an immune response to a virus.
Scientists are still studying key aspects of the virus, including how the immune system reacts when a person becomes infected. The answers, they said, could have important implications for developing a vaccine, including how quickly it could be distributed to the public.
The United States plans to distribute 300 million doses of the COVID-19 vaccine by early 2021.
Dr. Anthony Fauci, the country's leading infectious disease specialist, has often praised the potential vaccine for Moderna. He said scientists could create at least one safe and effective vaccine by the end of the year or early 2021.
stdClass Object ([term_id] => 1 [name] => Miscellaneous [taxonomy] => category [slug] => no_theme)Miscellaneous
stdClass Object ([term_id] => 4062 [name] => vaccine [taxonomy] => post_tag [slug] => vaktsina)vaccine
stdClass Object ([term_id] => 13992 [name] => Likbez [taxonomy] => category [slug] => poleznaja-informatsija)Educational program
stdClass Object ([term_id] => 28340 [name] => coronavirus [taxonomy] => post_tag [slug] => koronavirus)coronavirus
stdClass Object ([term_id] => 28347 [name] => Special projects [taxonomy] => category [slug] => specproekty)Special Projects
stdClass Object ([term_id] => 28353 [name] => READ ABOUT CORONAVIRUS [taxonomy] => special [slug] => kitajskij-koronavirus)
Read also on ForumDaily:
Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. And don't forget to subscribe to ForumDaily Woman and ForumDaily New York - there you will find a lot of interesting and positive information.